Clinical trial
Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas
NCT00463073 · Rigshospitalet, Denmark, Other · Completed
Key facts
| NCT number | NCT00463073 |
|---|---|
| Title | Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas |
| Official title | A Phase II Trial With Cetuximab, Bevacizumab and Irinotecan for Patients With Malignant Glioblastomas and Progression After Radiation Therapy and Temozolamide |
| Lead sponsor | Rigshospitalet, Denmark, Other |
| Collaborators | Aalborg University Hospital Odense University Hospital |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Malignant Gliomas |
| Intervention type | Drug |
| Interventions | Cetuximab, Bevacizumab, Irinotecan |
| Enrollment | 32 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Apr 20, 2007 |
| Last update posted | Dec 11, 2008 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: